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Abstract
Background: The purpose of this study was to produce a risk stratification within a population of high-risk patients
with multiple chronic conditions who are currently treated under a case management program and to explore the
existence of different risk subgroups. Different care strategies were then suggested for healthcare reform according
to the characteristics of each subgroup.
Methods: All high-risk multimorbid patients from a case management program in the Navarra region of Spain
were included in the study (n = 885). A 1-year mortality risk score was estimated for each patient by logistic
regression. The population was then divided into subgroups according to the patients’ estimated risk scores. We
used cluster analysis to produce the stratification with Ward’s linkage hierarchical algorithm. The characteristics of
the resulting subgroups were analyzed, and post hoc pairwise tests were performed.
Results: Three distinct risk strata were found, containing 45, 38 and 17% of patients. Age increased from
cluster to cluster, and functional status, clinical severity, nursing needs and nutritional values deteriorated.
Patients in cluster 1 had lower renal deterioration values, and patients in cluster 3 had higher rates of
pressure skin ulcers, higher rates of cerebrovascular disease and dementia, and lower prevalence rates of
chronic obstructive pulmonary disease.
Conclusions: This study demonstrates the existence of distinct subgroups within a population of high-risk
patients with multiple chronic conditions. Current case management integrated care programs use a uniform
treatment strategy for patients who have diverse needs. Alternative treatment strategies should be considered
to fit the needs of each patient subgroup.
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Background
Decades of progressive declines in the burden of com-
municable diseases and consequent improvements in life
expectancy have shifted clinical and managerial concerns
towards chronic illnesses, which are reaching alarming
levels of prevalence in aging societies [1, 2].
Special attention has been given to multimorbidity [3,
4] and high-risk multiple chronic condition (MCC) pa-
tients in particular. Despite representing a small share of
the chronic patient population, high-risk MCC patients
account for a great share of healthcare organization bud-
gets [5]. The elevated number of consultations, hospitali-
zations, and other treatments from different,
uncoordinated specialties decreases favorable outcomes
and increases cost [6].
Plans for appropriate management and delivery of care
in the context of high-risk patients focus efforts on the
realignment of systems towards case management inte-
grated care programs [1, 7]. These models plan and co-
ordinate care around specific high-risk patients through
the assignment of a reference physician or a small multi-
disciplinary team. Teams assess the individual needs of
each patient, develop a care plan accordingly and coord-
inate treatment delivery. Patients are monitored with
periodic reassessments [8].
Identifying patients for which case management would
be appropriate is an essential element of programs of
this nature, and it is usually done by means of risk strati-
fication techniques that classify patients with similar
clinical needs into homogeneous groups [9]. This re-
quires the establishment of a risk score using statistical
models together with judgments from clinicians and the
formation of certain thresholds for the assignment of pa-
tients to different risk strata [10].
In general terms, candidates for case management be-
long to the top 5% risk stratum of the population and are
identified using a variety of ready-to-use risk stratification
tools, including clinical risk groups (CRGs), adjusted clin-
ical groups, diagnosis-related groups, diagnostic cost
groups or the senior segmentation algorithm among
others [9, 11–13]. A set of common services can be pro-
vided where risk stratification produces a homogeneous
group of patients, and if needs are appropriately ad-
dressed, case management will fit patients in a cost-
effective way, avoiding wasteful, unnecessary care.
However, evidence has shown that case management
programs are not cost-effective in comparison to nonin-
tegrated care programs for high-risk patients [7, 8, 14].
Case management interventions are not suitable for all
high-risk patients but for a subset of patients who would
benefit from them [14]. In other words, the population
they target is heterogeneous and has different needs [10,
15–17], yet all patients are treated in a uniform manner
under the same case management strategy. Since some
groups of patients are receiving a type of care that does
not fit their needs, care provides minimal or no health
benefit to those patient subgroups and does not justify
the costs, translating into low-value care for some of the
patients in the high-risk population [18].
Therefore, case management requires further stratifi-
cation to identify those patient subgroups that do not
benefit from their current care and to adapt care strat-
egies for them. The purpose is to target appropriate care
for the appropriate patients. By reorganizing high-risk
integrated care programs, we aim to target new services
to selected groups of patients that are most likely to
benefit from them. The extent to which newly organized
services fit the clinical needs of patient subgroups will
determine both improvements in outcomes and the de-
gree of efficiency in healthcare resource utilization.
The purpose of this study was to produce a restratifi-
cation within the high-risk MCC patient population, ex-
ploring the existence of different risk subgroups.
Subsequently, the characteristics of each risk stratum
were defined. Finally, we proposed different care strat-
egies according to the risk profile of each subgroup, tai-
loring integrated care for high-risk patients.
Methods
Data and participants
In 2016, the Navarra region of Spain implemented an in-
tegrated care program for the treatment of chronic ill-
ness, which included a case management model for
high-risk, noncancer MCC patients [19]. This study in-
cluded all high-risk MCC patients who were treated in
the region’s case management program from April 2016
– August 2018. The conditions to qualify for program
enrollment were as follows:
Patients suffered at least three selected noncancer
pathologies, including heart failure, dementia, ischemic
heart disease, cerebrovascular disease, diabetes, chronic
obstructive pulmonary disease, asthma, chronic renal
failure and cirrhosis, and patients belonged to the top
5% of the risk pyramid according to the adjusted mor-
bidity groups (GMA). GMA is a stratification tool simi-
lar to CRGs that is widely applied in Spain [20, 21]. A
total of 885 patients were considered.
Data were obtained from the high-risk case manage-
ment program database, which is anonymized and in-
cludes sociodemographic data, as well as data regarding
functional status (Barthel score), nutritional status (serum
albumin), renal deterioration status (creatinine, albumin/
creatinine index), the presence of pressure skin ulcers, the
number of prescriptions, prevalence and number of coex-
isting selected illnesses and the GMA risk score. In
addition, the database also incorporates professionally
rated variables such as clinical severity, nursing needs and
social needs. A combination of the former is also available
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as global severity status. All variables were measured at
patient inclusion in the program, when patients under-
went a comprehensive assessment of their situation. Miss-
ing values were filled using multiple imputation to avoid
biases in risk score estimation and subsequent stratifica-
tion (Table 2) [22].
Producing a risk score
A risk score was estimated for each of the patients using
data from the initial comprehensive assessment that was
completed upon inclusion in the case management pro-
gram. The outcome for this risk score estimation was 1-
year mortality from enrollment in the case management
program. The reason why mortality was used as the out-
come was that our population of interest consisted of
patients with different chronic illness combinations.
Therefore, disease-specific outcomes were not appropri-
ate, as it was not possible to apply them to all patients
under study. A common outcome was needed, and 1-
year mortality was selected.
The risk score was estimated by logistic regression,
where we first tested all variables in univariate analyses.
Those variables that were significant were then fitted
into a multivariate model, and insignificant variables
were eliminated from the model in a stepwise manner.
Significant predictors included the functional status, cre-
atinine value, global severity status and presence of pres-
sure skin ulcers. The results were validated using cross-
validation techniques, as well as bootstrapping. A full de-
scription of the risk score estimation process is available
in another published study [23]. Subsequently, patients
were categorized into different ‘buckets’ or clusters ac-
cording to their estimated risk [24].
Risk stratification
For the purpose of determining patient subgroups and
categorizing individuals into distinct, mutually exclusive
risk strata, we used machine learning algorithms. These
techniques group individuals who have similar risk
scores into subgroups that are dissimilar and are more
frequently termed cluster analysis [25].
We used Ward’s linkage hierarchical algorithm with
the squared Euclidian distance (L2squared). The optimal
number of clusters was determined using the Duda/Hart
stopping rule and visually through a dendrogram (Fig. 1).
A dendrogram is a diagram that shows how observations
merge with other observations that are similar to them
in terms of distance. Those observations that are closest
to them, or equivalently those that have the most similar
risk scores, are merged into a group. This process con-
tinues iteratively, and larger, distinct groups can be ob-
served in the dendrogram. Mergers are represented as
nodes, and the distance between groups of patients is
shown in the vertical axis. The results were validated
using silhouettes, reassigning individuals to a different
cluster when needed [26].
To evaluate the stability of the results, the full sample
was randomly divided into four equally sized subsam-
ples, each containing 25% of the observations, and the
algorithm was run again on each subsample. It is pos-
sible to think about this process as k-fold cross valid-
ation with four folds. The robustness of the results was
further tested by running the K-means algorithm, setting
the parameter k equal to Ward’s linkage optimal number
of clusters. Table 1 shows how many patients belong to
each cluster when using the two clustering techniques
used in this study, Ward’s linkage algorithm, and K-
Fig. 1 Patient grouping process (dendrogram)
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means algorithm that was performed as a robustness
check. In addition, the number of patients in each of the
four randomly divided subsamples from stability analysis
is shown.
Cluster examination
Following the identification of patient subgroups, their
clinical and sociodemographic characteristics were com-
pared to test if there were significant differences between
them. The prevalence of chronic illness diagnoses and
their most frequent combinations were also compared.
When considering continuous variables, one-way
ANOVA tests were performed. Kruskal-Wallis tests were
used when considering categorical variables or if the as-
sumptions for ANOVA did not hold, and a χ2 test was
used for binary variables. If significant differences in pa-
tient characteristics were observed across clusters, fur-
ther post hoc pairwise tests were completed to detect
which cluster was different from the remaining clusters.
Multiple one-way ANOVA comparisons with Bonferroni
corrections, Mann-Whitney U tests and Fisher’s exact
tests were used if ANOVA, Kruskal-Wallis or χ2 tests
were used, respectively. All analyses were carried out
using STATA 15.0 software.
Results
Clustering results
Both the Duda/Hart stopping rule and the clustering
process dendrogram (Fig. 1), which shows the last 100
grouping nodes, indicated the presence of three distinct
clusters within the high-risk MCC patient population.
The optimal number of clusters was also assessed con-
sidering its clinical relevance and interpretability.
The clusters were ordered in such a way that the 1-
year mortality risk scores were incremental. Hence, pa-
tients with the lowest risk scores belong to cluster 1,
cluster 2 includes intermediate cases, and very high-risk
patients have been allocated to cluster 3. With respect to
the distribution of patients among clusters, cluster 1 in-
cluded ≃45% of patients, ≃38% were classified into clus-
ter 2, and ≃17% were assigned to cluster 3.
The structure of the data remained constant in the sta-
bility analysis, showing that the patterns in the subgroup
distribution were reproducible even if random parts of
the sample were excluded. Table 1 shows one of the
many random partitions that were carried out, all with
very similar results. The K-means algorithm also showed
a similar pattern in the data, producing roughly the same
patient distribution among clusters. Generally, these ro-
bustness checks confirmed that the 3-cluster solution
and the resulting proportion of patients assigned to each
cluster were robust.
Cluster characteristics
The representative features of each cluster are described
in Tables 2 and 3. We report mean values or propor-
tions, together with the significance test p-values and
post hoc test results.
Some of the reported variables varied across clusters.
Age increased significantly from one cluster to the next.
The Barthel scale was significantly different for all patient
types, showing extensive declines in functional status from
cluster to cluster. Moreover, serum albumin values were
also significantly different across clusters, indicating
poorer nutritional status. The majority of professional-
rated variables increased significantly among clusters, as
shown by global status, clinical severity and nursing needs.
Social needs were the exception in this group of variables,
as no significant differences were reported.
We can therefore say that mortality risk scores in-
crease as age progresses, alongside a deterioration of
functional status, nutritional values, clinical severity sta-
tus and nursing needs status (Table 2). While these
trends are common to all patients, certain features in-
herent to particular clusters were observed:
▪ Cluster 1: risk scores [0–26.70%]
Patients in this cluster showed a lower renal
deterioration degree, as measured by creatinine, in
comparison to the rest of the clusters. The number of
prescriptions and the proportion of patients who had
an informal caregiver were significantly lower than
Table 1 Distribution of patients among clusters
Cluster 1 Cluster 2 Cluster 3
Ward’s linkage (n = 885) 400 (45.20%) 336 (37.96%) 149 (16.84%)
Stability Analysis
Sub-Sample 1 (n = 221; 25%) 91(41.18%) 91(41.18%) 39(17.64%)
Sub-Sample 2 (n = 221; 25%) 98 (44.34%) 89 (40.28%) 34 (15.38%)
Sub-Sample 3 (n = 221; 25%) 105 (47.52%) 74 (33.48%) 42 (19.00%)
Sub-Sample 4 (n = 222; 25%) 100 (45.05%) 88 (39.64%) 34 (15.32%)
Total (n = 885) 394 (44.52%) 342 (38.64%) 149 (16.84%)
K-means (n = 885) 370 (41.81%) 348 (39.32%) 167 (18.87%)
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Table 2 Patient Characteristics within Clusters







1-year mortality risk score (%) 32.15 ± 18.04% 16.95 ± 6.45% 36.64 ± 6.67% 62.84 ± 10.68% KW < 0.001a
Age (mean ± s.d.) 83.33 ± 8.37 81.16 ± 8.51 84.32 ± 8.05 86.89 ± 6.97 KW < 0.001a
Sex (% Males) 56% 62% 55% 44% χ2 < 0.001c
Informal Caregiver (%) 91% 88% 94% 93% χ2: 0.011d
GMA score (mean ± s.d.) 22.81 ± 6.82 22.47 ± 6.39 23.04 ± 7.06 23.24 ± 7.33 AN: 0.379
Barthel scale (mean ± s.d.) 59.95 ± 29.45 82.03 ± 18.16 51.64 ± 17.24 19.40 ± 22.15 KW < 0.001a
Albumin/creatinine index (mean ± s.d.) 1.49 ± 0.67 1.49 ± 0.66 1.51 ± 0.70 1.46 ± 0.66 KW: 0.792
≤30mg/g: Normal (n, %) 540 (61%) 242 (61%) 203 (60.42%) 95 (64%)
30–300mg/g: Moderate (n, %) 254 (29%) 120 (30%) 94 (28%) 40 (27%)
≥300mg/g: High (n, %) 91 (10%) 38 (9%) 39 (12%) 14 (9%)
Creatinine (mg/dL) (mean ± s.d.) 1.52 ± 0.78 1.40 ± 0.59 1.57 ± 0.75 1.72 ± 1.16 KW: 0.002b
Serum albumin (g/dL) (mean ± s.d.) 3.80 ± 0.43 3.90 ± 0.37 3.76 ± 0.41 3.59 ± 0.50 KW < 0.001a
Pressure skin ulcers (%) 28% 21% 26% 55% χ2 < 0.001c
Number of prescriptions (mean ± s.d.) 8.08 ± 3.55 7.82 ± 3.48 8.47 ± 3.75 7.95 ± 3.20 AN: 0.038d
Intake of opioids (%) 15% 17% 12% 13% χ2: 0.168
Intake of psycholectics (%) 8% 5% 9% 16% χ2 < 0.001c
Global severity (mean ± s.d.) 2.87 ± 0.45 2.63 ± 0.50 2.99 ± 0.09 3.22 ± 0.41 KW < 0.001a
Mild (n, %) 4 (< 1%) 4 (1%) – –
Moderate (n, %) 144 (16%) 141 (35%) 3 (1%) –
Severe (n, %) 704 (80%) 25 (64%) 333 (99%) 116 (78%)
Very severe (n, %) 33 (4%) 33 (22%)
Clinical severity (mean ± s.d.) 3.30 ± 0.68 3.09 ± 0.75 3.43 ± 0.59 3.58 ± 0.55 KW < 0.001a
Mild (n, %) 2 (< 1%) 2 (1%) – –
Moderate (n, %) 110 (12%) 89 (22%) 17 (5%) 4 (3%)
Severe (n, %) 393 (44%) 180 (45%) 158 (47%) 55 (37%)
Very severe (n, %) 380 (43%) 129 (32%) 161 (48%) 90 (60%)
Nursing needs (mean ± s.d.) 2.65 ± 0.88 2.23 ± 0.80 2.82 ± 0.77 3.41 ± 0.66 KW < 0.001a
Mild (n, %) 76 (9%) 66 (16%) 10 (3%) –
Moderate (n, %) 323 (36%) 204 (51%) 105 (31%) 14 (10%)
Severe (n, %) 318 (36%) 103 (26%) 155 (46%) 60 (40%)
Very severe (n, %) 168 (19%) 27 (7%) 66 (20%) 75 (50%)
Social needs (mean ± s.d.) 1.77 ± 0.70 1.71 ± 0.68 1.82 ± 0.71 1.84 ± 0.73 KW: 0.095
Mild (n, %) 327 (37%) 162 (40%) 116 (35%) 49 (33%)
Moderate (n, %) 451 (51%) 199 (50%) 173 (51%) 79 (53%)
Severe (n, %) 90 (10%) 33 (8%) 40 (12%) 17 (11%)
Very severe (n, %) 17 (2%) 6 (2%) 7 (2%) 4 (3%)
KW Kruskal-Wallis test, AN ANOVA, χ2 Chi-squared test
Missing values that were imputed for analysis (% missing): creatinine (0.23%), albumin/creatinine index (2.15%) clinical severity (3.62%), nursing needs (9.38%),
global severity (10.96%), Barthel scale (14.24%), serum albumin (15.71%), social needs (43.62%)
aAll clusters are significantly different from each other
bCluster 1 is significantly different to the remaining clusters
cCluster 3 is significantly different to the remaining clusters
dClusters 1 and 2 are significantly different, but there were no other differences in the remaining pairwise post hoc tests
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those of cluster 2, but there were no significant
differences with respect to cluster 3.
▪ Cluster 2: risk scores [26.70–50.80%]
No particular differences were reported with respect to
the other clusters, apart from the common differences
that relate to age, functional status, nutritional values
and the professional-rated variables mentioned above.
▪ Cluster 3: risk scores [50.80–100%]
All patients included in this subgroup had a higher
likelihood of dying than of surviving the following year.
Regarding specific cluster features, we found a higher
proportion of female patients than in other subgroups.
Patients included in this subgroup presented a notable
increase in the existence of pressure ulcers, with more
than 50% of them presenting this problem. Regarding
diagnosis, patients in this cluster presented a significantly
lower prevalence rate of COPD but higher prevalence
rates of cerebrovascular disease and dementia in
comparison to those in clusters 1 and 2. In line with the
higher prevalence of dementia, a higher intake of
psycholectics also was observed.
Despite the many differences described above, some
other characteristics remained unchanged across clus-
ters. This was the case for the albumin/creatinine index,
which is an early screener for kidney disease, the intake
of opioids, and social needs, as highlighted earlier.
The GMA risk score, which was the metric used to select
the top 5% of risks for our study, was similar for all clusters.
That is, while the mortality risk scores varied among differ-
ent clusters, the GMA risk scores remained the same.
All other diagnoses apart from COPD, cerebrovascular
disease and dementia had similar prevalence rates
among the clusters. Regarding the most frequent illness
combinations present in our population, no significant
differences across clusters were observed (Table 3). The
number of coexisting chronic conditions was also equal
in all subgroups.
Table 3 Patient Diagnoses within Clusters
















Prevalence of illnesses χ2 test
Diabetes (n, %) 635 (72%) 289 (72%) 237 (71%) 109 (73%) p: 0.803
Chronic Renal Failure (n, %) 591 (67%) 257 (64%) 234 (70%) 100 (67%) p: 0.301
Ischemic Heart Disease (n, %) 444 (50%) 212 (53%) 169 (50%) 63 (42%) p: 0.082
Heart Failure (n, %) 595 (67%) 267 (67%) 234 (70%) 94 (63%) p: 0.352
Cerebrovascular Disease (n, %) 283 (32%) 113 (28%) 106 (32%) 64 (43%) p: 0.004a
COPD (n, %) 263 (30%) 135 (34%) 102 (30%) 26 (17%) p: 0.001a
Asthma (n, %) 190 (21%) 98 (25%) 66 (20%) 26 (17%) p: 0.118
Dementia (n, %) 166 (19%) 56 (14%) 60 (18%) 50 (34%) p <
0.001a
Cirrhosis (n, %) 68 (8%) 36 (9%) 26 (8%) 6 (4%) p:0.151
Most frequent illness combinations
Diabetes + Chronic Renal Failure + Heart Failure (n, %) 67 (8%) 26 (7%) 29 (9%) 12 (8%) p: 0.537
Diabetes + Chronic Renal Failure + Heart Failure + Ischemic Heart Disease
(n, %)
50 (6%) 20 (5%) 19 (6%) 11 (7%) p: 0.561
Chronic Renal Failure + Heart Failure + Ischemic Heart Disease (n, %) 36 (4%) 16 (4%) 16 (5%) 4 (3%) p: 0.563
Diabetes + Chronic Renal Failure + Ischemic Heart Disease (n, %) 34 (4%) 16 (4%) 16 (5%) 2 (1%) p: 0.190
Diabetes + Heart Failure + Ischemic Heart Disease (n, %) 25 (3%) 14 (4%) 5 (1%) 6 (4%) p: 0.162
Diabetes + Heart Failure + COPD (n, %) 25 (3%) 13 (3%) 8 (2%) 4 (3%) p: 0.773
Chronic Renal Failure + Heart Failure + COPD 17 (2%) 10 (3%) 6 (2%) 1 (1%) p: 0.372
Heart Failure + Ischemic Heart Disease + Cerebrovascular Disease (n, %) 18 (2%) 5 (1%) 10 (3%) 3 (2%) p: 0.255
Diabetes + Heart Failure + Cerebrovascular Disease (n, %) 18 (2%) 7 (2%) 7 (2%) 4 (3%) p: 0.786
Diabetes + Chronic Renal Failure + Heart Failure + Asthma (n, %) 15 (2%) 10 (3%) 2 (1%) 3 (2%) p: 0.130
χ2 Chi squared test
aCluster 3 is significantly different to the remaining clusters
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Discussion
This study demonstrates the existence of clinically dis-
tinct subgroups within the a population of high-risk pa-
tients with multiple chronic conditions, confirming that
case management integrated care programs use a uni-
form treatment strategy for patients who have diverse
needs. That is, case management treats heterogeneous
populations in a homogeneous way.
The need for a data-based, high-risk patient stratifica-
tion has been extensively illustrated in the literature, but
despite its potential it remains underdeveloped, and only
a few studies exist [27]. One of the reasons why this may
be the case is that proprietary stratification algorithms
such as CRGs are already in place, so healthcare profes-
sionals or managers do not see the necessity of using al-
ternative approaches. However, while these algorithms
provide considerably better solutions than demographic
approaches, they are poor risk adjusters when mortality
and other clinical outcomes are considered [21, 24].
There is a lack of alignment between the purpose of pro-
prietary algorithms, which aim to stratify patient popula-
tions based on estimates of future healthcare resource
consumption [13], and the purpose of this study, that is,
to stratify patients according to their clinical needs.
Our results support these statements and show how the
GMA score, the Spanish equivalent of CRGs, does not
vary across subgroups, whereas mortality risk scores do
differ from cluster to cluster. GMA does not offer the de-
sired level of granularity to observe clinically relevant sub-
populations among high-risk patients, resulting in a
homogeneous population from a cost point of view, while
subpopulations with different needs remain undetected if
alternative risk stratification methods are not introduced.
Given that ready-to-use risk stratification tools are not
adequate for the purposes of this study, alternative seg-
menting methods were explored. Big data techniques
and cluster analysis in particular have been proposed for
these purposes in the literature when electronic records
are available, as in our case [9, 16, 28]. We showed that
cluster analysis is a useful tool for producing risk stratifi-
cations, providing valuable information for healthcare
reform and robust results that are easy to interpret.
With respect to the variables that were used to stratify
our population, only clinically related and demographic
variables were used. This approach offers several advan-
tages, emphasizing relevant health priorities that should
be addressed and informing the design of new services
or the reform of the existing ones [27]. In contrast, the
demand for healthcare services does not always inform
areas of clinical concern but of cost concern. Health re-
forms that arise from using utilization rates for risk
stratification may go against the interest of the patient,
since the aim of the policy maker may be to reduce costs
instead of improve population health [29].
Moreover, if utilization rates are to be used, episodes
of care should be comparable [24]. All patients should
suffer the same health problem or diagnosis, and all de-
mand episodes should be related to the medical area of
interest and equally intense or of the same nature. If the
former conditions are fulfilled, the quantity of care pro-
vided is appropriate for risk stratification. However, this
is hardly ever the case, especially in the case of chronic
illnesses, and in our study in particular, patients suffered
different illness combinations or types of exacerbations,
making utilization episodes incomparable.
A limitation of our study is that the population under
study suffered from a specific set of chronic illnesses
that may not be the same in other settings. In addition,
patients only qualified for enrollment if they suffered
from three or more chronic illnesses. Other programs
may require only two chronic illnesses for enrollment.
This may impact the generalizability of our study results.
Moreover, we tested the cluster stability and robustness
internally rather than externally. As a final limitation, we
specified patient clusters using our own risk score esti-
mations. However, different risk scoring models are
likely to be used in other environments. We encourage
others to reproduce our analyses and estimate risk
scores for each context.
One study by Vuik et Al. [30] stratified a high-risk pa-
tient population using cluster analysis. However, that
study grouped patients according to their utilization pat-
terns and not their clinical risk scores or needs. More-
over, cancer patients were included while we did not
include this type of patient. Four main subgroups among
which care usage had significant variation were identi-
fied. Low et Al. [31] also provided a risk stratification
using cluster analysis, using utilization data to group pa-
tients. Their study was not restricted to high-risk pa-
tients and included all types of adult patients in the
analysis, without making distinctions in terms of their
risk category or clinical profile. Five clusters were found.
Other studies that segment patient populations are
available in the literature, although they used expert cri-
teria to produce the resulting subgroups instead of data-
driven approaches [17, 32]. Lynn et al. describe three
end-of-life subgroups for frail, high-risk patients, which
is in line with our results.
Tailoring integrated care services
To date, all patients included in this study have been
treated under the same case management strategy.
Nevertheless, three distinct subgroups with different
characteristics were identified for which care programs
should be tailored.
We proposed a different care strategy for each type of
patient so that treatment can adequately meet patient
needs. These strategies were based on a literature review
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and supported by expert consultation with healthcare
authorities from the region who have extensive experi-
ence with the integrated care program under study.
Patients included in cluster 1, whose risk status was
the lowest of all subgroups and who had moderate func-
tional status, severity status and nursing needs, could
benefit from their current case management program.
This program includes a reference specialist team that
keeps patient follow-up, self-care education and support,
a link nurse that is available 24 h by phone, and most
importantly, direct hospital admission without passing
through emergency services and a day hospital unit. At-
home services are also available in some cases. All pro-
fessionals develop personalized care plans that focus on
avoiding exacerbations and sustaining function.
As health starts to decline in combination with a wors-
ening functional status and increasing nursing needs, pa-
tients become increasingly dependent on a 3rd person,
and transitions from home to the hospital can be com-
plicated. Patients in cluster 2 would benefit from home-
based programs that focus on improving quality of life
and averting unnecessary hospitalizations or readmis-
sions [32]. Mobile integrated care programs should be
implemented for these purposes [33]. Nursing services,
together with caregiver training and support, play an im-
portant role.
Those included in cluster 3, with the highest mortality
risk scores, are very likely to die in the near future. Con-
tinuing functional declines, together with worsening
clinical severity and other characteristics such as in-
creases in pressure skin ulcers or higher rates of demen-
tia and cerebrovascular disease, are indicators of the
short survival prospect of patients included in this sub-
group. Healthcare services should be directed towards
end-of-life care, including hospices, or home-based pal-
liative care services that shift attention from curative ef-
forts to quality of life improvements [34].
A risk score estimation tool has been created for use
in clinical practice to estimate patient risk scores [23].
This tool consists of a nomogram, which is a graphical
calculation tool that synthesizes logit model results in a
graph that is filled in by healthcare professionals and
provides individual risk scores for each patient without
the need for computers or software. Risk scores, in com-
bination with the results of this study, can be used in
clinical practice for patient classification purposes. Risk
score calculation and subsequent patient classification
should be performed at patient enrollment in the pro-
gram but also at regular intervals or if healthcare profes-
sionals see it as necessary. This would allow close
monitoring of each patient situation, providing valuable
information that can assist treatment strategy decisions.
This study is a key part of the design of alternatives to
case management care programs. By stratifying the
population into differentiated subpopulations, we identi-
fied relevant patient types and their needs. The descrip-
tion of the characteristics of each patient type can guide
the development of these new services. Moreover, study
results provide valuable information for healthcare pro-
fessionals in relation to the development of each
patient’s condition and can assist treatment strategy
decisions.
The extent to which patient outcomes such as mortal-
ity rates or quality of life improve will be determined in
future research when alternative programs are imple-
mented and their performance measured. The efficiency
of new care strategies also needs to be measured in
future research through cost-effectiveness analyses.
Conclusions
This study produced a restratification for a population
of high-risk multimorbid patients who are currently in-
cluded in a case management integrated care program.
We showed that the high-risk population had heteroge-
neous needs but that all patients received the same treat-
ment. Risk stratification was performed using cluster
analysis. The characteristics of each cluster were pre-
sented, outlining the specific needs that should be ad-
dressed in healthcare reform. We suggested alternatives
to case management services that can make meaningful
contributions to health outcomes, moving away from
low-value care.
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